TY - JOUR
T1 - Plasma Sphingolipids Mediate a Relationship between Type 2 Diabetes and Memory Outcomes in Patients with Coronary Artery Disease Undertaking Exercise
AU - Eakin, Kelsey A.
AU - Saleem, Mahwesh
AU - Herrmann, Nathan
AU - Cogo-Moreira, Hugo
AU - Mielke, Michelle M.
AU - Oh, Paul I.
AU - Haughey, Norman J.
AU - Venkata, Swarajya L.V.
AU - Lanctôt, Krista L.
AU - Swardfager, Walter
N1 - Funding Information:
The sphingolipidome might be an important source of heterogeneity in the presentation of CAD that can indicate contributions of T2DM to cognitive decline. Some of the specific sphingolipids associated with This work was supported by grants from the Diabetic Complications Consortium (16GRU3711), the University of Toronto Centre for Collaborative Drug Research, The Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, the National Sciences and Engineering Research Council (RGPIN-2017-0692), the Canadian Institutes of Health Research (MOP-114913 [KLL] and PJT-159711 [WS]), and by the Alzheimer’s Association Research Grant Program (USA) in partnership with Brain Canada (AARG501466).
Publisher Copyright:
© 2019 -IOS Press and the authors. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: Exercise prevents recurrent cardiovascular events and it may combat cognitive decline in coronary artery disease (CAD); however, evidence in type 2 diabetes (T2DM) has been mixed. T2DM and memory decline have been associated with differences in the plasma sphingolipidome. Objective: Here, we will investigate whether T2DM-related sphingolipids predict less memory improvement over an exercise intervention for CAD. Methods: Among participants with CAD entering a 6-month exercise intervention, we matched 20 with T2DM to 40 without T2DM for age, sex, and body mass index. We assessed 45 sphingolipid species using high-performance liquid chromatography coupled electrospray ionization tandem mass spectrometry with multiple reaction monitoring. We assessed memory using the California Verbal Learning Test, 2nd Ed, and the revised Brief Visuospatial Learning Test. Results: Partial least squares discriminant analysis identified 8 species that distinguished T2DM from non-T2DM groups with 83% (95% confidence interval [70%, 95%]) accuracy in a receiver operator characteristic curve (validated by internal resampling, 1000 permutations, p=0.01). At baseline, T2DM-associated sphingolipids (ceramide C22:0, monohexylceramide C16:1, and lactosylceramide C24:0) were associated with poorer memory, attention, and psychomotor processing speed performance. Among 50 completers, an indirect effect of T2DM on less improvement in verbal memory was mediated by monohexylceramide C16:1 (0.86 fewer words recalled, 95% bootstrap confidence interval [-2.32, -0.24]), and an indirect effect of T2DM on less visuospatial memory improvement was mediated by ceramide C22:0 concentrations (0.42 fewer points, 95% bootstrap confidence interval [-1.17, -0.05]). Conclusions: Ceramide species associated with T2DM predicted poorer cognitive responses to exercise in patients with CAD.
AB - Background: Exercise prevents recurrent cardiovascular events and it may combat cognitive decline in coronary artery disease (CAD); however, evidence in type 2 diabetes (T2DM) has been mixed. T2DM and memory decline have been associated with differences in the plasma sphingolipidome. Objective: Here, we will investigate whether T2DM-related sphingolipids predict less memory improvement over an exercise intervention for CAD. Methods: Among participants with CAD entering a 6-month exercise intervention, we matched 20 with T2DM to 40 without T2DM for age, sex, and body mass index. We assessed 45 sphingolipid species using high-performance liquid chromatography coupled electrospray ionization tandem mass spectrometry with multiple reaction monitoring. We assessed memory using the California Verbal Learning Test, 2nd Ed, and the revised Brief Visuospatial Learning Test. Results: Partial least squares discriminant analysis identified 8 species that distinguished T2DM from non-T2DM groups with 83% (95% confidence interval [70%, 95%]) accuracy in a receiver operator characteristic curve (validated by internal resampling, 1000 permutations, p=0.01). At baseline, T2DM-associated sphingolipids (ceramide C22:0, monohexylceramide C16:1, and lactosylceramide C24:0) were associated with poorer memory, attention, and psychomotor processing speed performance. Among 50 completers, an indirect effect of T2DM on less improvement in verbal memory was mediated by monohexylceramide C16:1 (0.86 fewer words recalled, 95% bootstrap confidence interval [-2.32, -0.24]), and an indirect effect of T2DM on less visuospatial memory improvement was mediated by ceramide C22:0 concentrations (0.42 fewer points, 95% bootstrap confidence interval [-1.17, -0.05]). Conclusions: Ceramide species associated with T2DM predicted poorer cognitive responses to exercise in patients with CAD.
KW - Cognition
KW - coronary artery disease
KW - exercise
KW - memory
KW - sphingolipids
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85067091299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067091299&partnerID=8YFLogxK
U2 - 10.3233/JAD-181203
DO - 10.3233/JAD-181203
M3 - Article
C2 - 31006687
AN - SCOPUS:85067091299
SN - 1387-2877
VL - 69
SP - 717
EP - 727
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 3
ER -